An Open-Label Phase 1b Study of the Safety, Tolerability, and Preliminary Antitumor Activity of INCB059872 in Participants with Relapsed or Refractory Ewing Sarcoma
|Male and Female Patients
|U.S. Govt. ID:
|Research Nurse Navigator: 212-342-5162 / firstname.lastname@example.org
The main purpose of this research study is to test different doses of INCB059872 and see which doses are safe and tolerable in participants that have Ewing sarcoma. This study will research the effect that INCB059872 has on your cancer. Researchers will study the way INCB059872 come into and leave your body over time (pharmacokinetics). INCB059872 is a small-molecule selective inhibitor of LSD1.
This study is closed
Gary Schwartz, MD
|Are you 12 years or older?
|Do you have a confirmed diagnosis of Ewing sarcoma and have progressed on or after standard therapies?
|Are you able to provide a tumor sample?